Melissa Do
Physician Assistant · Dallas, TXNPI 1144849787
Payments from drug & device makers
Across 427 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- UCB, Inc.$943
- AbbVie$692
- Vanda Pharmaceuticals Inc.$520
- Eisai Inc.$437
- Acadia Pharmaceuticals Inc$366
- plus $6K from 52 others
What the payments were for
- Travel & lodging$8979%
- Food & beverage$9,28991%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,118
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$260
- SUNOSI$127
- QELBREE$125
How this compares
$10,202 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 38 | $73,074 |
| XcopriCenobamate | 50 | $63,803 |
| AptiomEslicarbazepine Acetate | 13 | $34,502 |
| OnfiClobazam | 11 | $34,459 |
| ValtocoDiazepam | 28 | $34,037 |
| FycompaPerampanel | 12 | $28,362 |
| RytaryCarbidopa/Levodopa | 15 | $19,242 |
| Lacosamide | 98 | $18,947 |
| LamictalLamotrigine | 12 | $15,364 |
| Sumatriptan Succinate | 17 | $9,635 |
| Levetiracetam | 99 | $4,948 |
| Lamotrigine ErLamotrigine | 13 | $4,575 |
| Felbamate | 12 | $4,196 |
| Clobazam | 28 | $3,709 |
| Levetiracetam ErLevetiracetam | 46 | $2,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $943 | $73,07438 claims |
| SK Life Science, Inc.Xcopri | $310 | $63,80350 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $80 | $34,50213 claims |
| Lundbeck LLCOnfi | $349 | $34,45911 claims |
| Neurelis, Inc.Valtoco | $282 | $34,03728 claims |
| Eisai Inc.Fycompa | $437 | $28,36212 claims |
| Amneal Pharmaceuticals LLCRytary | $41 | $19,24215 claims |
| Almatica Pharma LLCSertraline Hcl | $115 | $9120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Dallas
- Cynthia TrickettDallas$1.3M
- Michael WhiteDallas$276K
- Sofia NeicherilDallas$62K
- Shawn SommerladDallas$53K
- Katherine TurnerDallas$43K
- Tori BurnsDallas$39K
- Suzanne RaczDallas$32K
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.